Evidence map›Paper›PMID 36265469›Full record

ArticleCell systems2022

Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.

Nathan Guerin, Andreas Feichtner, Eduard Stefan, Teresa Kaserer, Bruce R Donald

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell systems, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. DexDesign: an OSPREY-based algorithm for designing de novo D-peptide inhibitors.Protein engineering, design & selection : PEDS · 2024
    Article
  5. A comprehensive study of SARS-CoV-2 main protease (MbioRxiv : the preprint server for biology · 2023
    Article
  6. Article
  7. RESISTOR: A New OSPREY Module to Predict Resistance Mutations.Journal of computational biology : a journal of computational molecular cell biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Nathan GuerinDepartment of Computer Science, Duke University, Durham, NC 27708, USA.
Andreas FeichtnerInstitute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, Innsbruck, 6020 Tyrol, Austria.
Eduard StefanInstitute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, Innsbruck, 6020 Tyrol, Austria; Tyrolean Cancer Research Institute, Innsbruck, 6020 Tyrol, Austria.
Teresa KasererInstitute of Pharmacy/Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, 6020 Tyrol, Austria. Electronic address: teresa.kaserer@uibk.ac.at.
Bruce R DonaldDepartment of Computer Science, Duke University, Durham, NC 27708, USA; Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA; Department of Chemistry, Duke University, Durham, NC 27708, USA; Department of Mathematics, Duke University, Durham, NC 27708, USA. Electronic address: brd+cellsys22@cs.duke.edu.
Universität Innsbruck · ATDuke University · USDuke University Hospital · US

Funding

Computational Structure-Based Protein DesignR01GM078031 · NIGMS · DUKE UNIVERSITY · PI DONALD, BRUCE R. · 2008 to 2021
$4.3M
Diversity Supplement: Computational and Experimental Studies of Protein Structure and DesignR35GM144042 · NIGMS · DUKE UNIVERSITY · PI Bruce R. Donald · 2022 to 2026
$3.2M
Deep Topological Sampling of Protein StructuresR01GM118543 · NIGMS · DUKE UNIVERSITY · PI DONALD, BRUCE R. · 2017 to 2020
$1.4M
Austrian Science Fund FWF P 30441NIGMS NIH HHS R01 GM078031NIGMS NIH HHS R01 GM118543NIGMS NIH HHS R35 GM144042
6 · The paper itself

Abstract

Resistance to pharmacological treatments is a major public health challenge. Here, we introduce Resistor-a structure- and sequence-based algorithm that prospectively predicts resistance mutations for drug design. Resistor computes the Pareto frontier of four resistance-causing criteria: the change in binding affinity (ΔK

Indexed as

Antineoplastic AgentsLung NeoplasmsAlgorithmsDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideGefitinibHumansLigandsMutationProspective StudiesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRetrospective StudiesAntineoplastic AgentsErbB ReceptorsErlotinib HydrochlorideGefitinibLigandsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAFcancercomputational protein designdabrafenibdrug resistanceEGFRencorafeniberlotinibgefitinibkinase conformation reporter assaykinase conformationsKinConmultistate designmutational signaturesosimertinibOSPREYPareto optimizationPLX8394resistance mutationsvemurafenib

Identifiers

PMID36265469
PMCPMC9589925
OpenAlexW4306797783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.